Prostate cancer trial shows improved survivability with additional hormone therapy
The Phase II/III clinical trial (STAMPEDE) currently being conducted by the University of Birmingham, UK, has demonstrated improved survivability of 37% with the use of an additional hormone therapy to treat prostate cancer patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Hormonal Therapy | Hormones | Pharmaceuticals | Prostate Cancer